The Latest Breaking News from ACADIA Pharmaceuticals Inc

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare market is booming. Amid this backdrop, investors could check out quality healthcare stocks ACADIA Pharmaceuticals (ACAD), Harvard Bioscience (HBIO), and LAVA Therapeutics (LVTX), which have significant upside potential. Continue reading.

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

Despite lingering macroeconomic headwinds, the broader market has shown remarkable fortitude this year and is poised for an even greater surge ahead. Hence, it could be wise to invest in fundamentally sound stocks Assurant (AIZ), ACADIA Pharmaceuticals (ACAD), and Accel Entertainment (ACEL), which have gained significant momentum lately. Continue reading….

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position.  RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.